anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Novel biomarkers are required in gastric cancer (GC) treated by immunotherapy. Epstein-Barr virus (EBV) infection induces an immune-active tumor microenvironment, while its association with immunotherapy response is still controversial. Genes underlying EBV infection may determine the response heterogeneity of EBV + GC. Thus, we screened hub genes associated with EBV infection to predict the response to immunotherapy in GC.
METHODS: Prognostic hub genes associated with EBV infection were screened using multi-omic data of GC. EBV + GC cells were established and confirmed by EBV-encoded small RNA in situ hybridization (EBER-ISH). Immunohistochemistry (IHC) staining of the hub genes was conducted in GC samples with EBER-ISH assay. Infiltrating immune cells were stained using immunofluorescence.
RESULTS: CHAF1A was identified as a hub gene in EBV + GC, and its expression was an independent predictor of overall survival (OS). EBV infection up-regulated CHAF1A expression which also predicted EBV infection well. CHAF1A expression also predicted microsatellite instability (MSI) and a high tumor mutation burden (TMB). The combined score (CS) of CHAF1A expression with MSI or TMB further improved prognostic stratification. CHAF1A IHC score positively correlated with the infiltration of NK cells and macrophages M1. CHAF1A expression alone could predict the immunotherapy response, but its CS with EBV infection, MSI, TMB, or PD-L1 expression showed better effects and improved response stratification based on current biomarkers.
CONCLUSIONS: CHAF1A could be a novel biomarker for immunotherapy of GC, with the potential to improve the efficacy of existing biomarkers.
BACKGROUND: There is limited evidence on the ideal retention thickness of skin flap in mastectomy. Residual breast tissue (RBT) after mastectomy still represents an unknown risk for local recurrence or new breast cancer lesions. We made this systematic review to identify the optimal flap after mastectomy with minimal complications and better oncological safety.
METHODS: A systematic review was performed using MEDLINE search in PubMed, Embase, and Cochrane Library with the search terms relevant to skin flap thickness and residual breast tissue in breast cancer patients undergoing mastectomy.
RESULTS: Twenty-one studies were included of which fifteen studies enrolled 3814 patients who received mastectomy, and additional six studies were based on cadavers or breast specimens. Four studies confirmed the presence of the superficial fascial layer (Camper's fascia) which can theoretically be used as an anatomical marker for flap retention during mastectomy. Two other studies confirmed Camper's fascia deficiency to a greater or lesser extent. The flap thickness ranged from 3.8 mm to 23 mm in 2692 patients of 7 studies, which was related to BMI, breast size, and examination modalities. Two retrospective and one prospective studies confirmed flaps exceeding 5 mm could significantly increase postoperative complications. Nine studies including 1122 patients explored the association among flap thickness, RBT, and complications, 3 studies of which confirmed excessive flap thickness could cause a significant increase in RBT, which proved to be a potential risk factor for local recurrence in 3 studies. Flaps beyond 5 mm were also found to significantly increase the chance of local recurrence in 4 studies.
CONCLUSION: Camper's fascia can serve as an ideal demarcation between fat and breast tissue based on most current studies. 5 mm thickness of the flap retention in mastectomy is recommended if Camper's fascia is absent or obscure, through which better cosmetic outcomes and less RBT can be achieved.
BACKGROUND: Esophagectomy in combination with perioperative multimodal therapy is the cornerstone of modern curative treatment for esophageal adenocarcinoma. The primary aim of this study was to assess the influence of textbook outcome (TO) as a composite quality performance indicator (QPI) and its perioperative parameters on survival in patients who underwent esophagectomy with curative intent.
METHODS: Consecutive patients who underwent an esophagectomy between January 2014 and December 2022 at Christchurch Hospital were identified from a prospectively maintained hospital database. Univariable and multivariable analyses were performed to assess prognostic factors for each composite and individual postoperative outcome. Survival analysis was performed to evaluate the influence of these outcomes on overall survival.
RESULTS: A total of 108 patients underwent an esophagectomy during the study period. The overall and Clavien-Dindo (CD) grade ≥ 3 postoperative complication rates were 62% and 26%, respectively. The anastomotic leak rate was 6.5% (n = 7). The TO rate, 30-day readmission rate, and 30-day mortality rate were 20%, 13%, and 1%, respectively. Resection margin and nodal disease were found to be independent prognostic factors for reduced survival.
CONCLUSION: TO as originally defined and its postoperative parameters of 30-day postoperative complications and 30-day readmission are validated QPIs of esophageal cancer surgery. Updating the postoperative complication parameter to include CD grade ≥ 3 complications resulted in a positive association between achieving TO and increased survival. Our findings support the call to redefine TO based on an update to this parameter, making it a more precise QPI of esophageal cancer surgery.
A glove-mountable system for pelvic floor muscle (PFM) examination includes a first flexible member including a force sensor configured to detect a force applied to a PFM of a patient by a user. A second flexible member includes an electromyography (EMG) electrode, a stimulation electrode, and a 3-D digitization probe. The second flexible member is stacked on the first flexible member and each flexible member is secured to an examination glove. An actuation button is actuated by the user when at least one point of interest is detected in at least on PFM. A computer including a processor and a memory is in communication with the first flexible member, the second flexible member and the actuation button. The computer generates a 3-D map of a plurality of PFMs of the patient based on data received from the first flexible member, the second flexible member and the actuation button.
PURPOSE: The relationship between thyroid hormone sensitivity and albuminuria remains unclear. We aimed to investigate the association between thyroid hormone sensitivity and the risk of albuminuria in a euthyroid population.
METHODS: This cross-sectional study included 7634 euthyroid adults collected from the National Health and Nutrition Examination Survey (NHANES) between 2007 and 2012. Central sensitivity to thyroid hormones was evaluated using the thyroid-stimulating hormone index (TSHI), the thyrotrophic thyroxine resistance index (TT4RI), and the thyroid feedback quantile-based index (TFQI). Peripheral sensitivity to thyroid hormones was measured using the free triiodothyronine/free thyroxine (FT3/FT4) ratio. Furthermore, the independent relationship between sensitivity to thyroid hormones and albuminuria was assessed.
RESULTS: The proportion of albuminuria increased with a higher interquartile range of TFQI levels (7.31% vs. 7.89% vs. 7.95% vs. 9.89%, P = 0.024). Furthermore, TFQI was found to be independently associated with the risk of albuminuria after adjusting for confounding factors (OR = 1.28, 95% CI 1.01-1.60, P = 0.037). Subgroup analysis revealed a significant relationship between TFQI and albuminuria, especially among individuals over 60.
CONCLUSIONS: In euthyroid subjects, impaired central sensitivity to thyroid hormones is associated with albuminuria. TFQI holds significant potential as an epidemiological tool for quantifying the impact of impaired central sensitivity on the risk of albuminuria.
The invention belongs to the field of fine chemical engineering, and particularly relates to a high-valence silver antibacterial agent and a preparation method thereof. The high-valence silver antibacterial agent is a silver-polyhexamethylene biguanidine complex with the electric potential zeta larger than 0. A metal part of the silver-polyhexamethylene biguanidine complex is Ag3+, and the antibacterial property of the complex is 200 times that of Ag+. A biological acceptable part is polyhexamethylene biguanidine (PHMB), compared with other guanidines with small molecular weights, the antibacterial property is good, the advantages are more obvious because of the synergistic antibacterial effect of PHMB and other antibiotics, and toxicity to cells and tissue of human bodies is smaller. The nanoscale or micron-size Ag(III)-PHMB complex high in antibacterial activity is prepared by means of reversed-phase microemulsion or the aqueous solution environment. On one hand, the Ag(III)-PHMB complex can reduce toxicity, and on the other hand, the metal part and the biological acceptable part achieve the synergistic antibacterial effect so that the antibacterial property of the antibacterial agent can be effectively improved. The antibacterial agent has a great significance in treatment of human epidermis infection.
BACKGROUND: Oncoplastic surgery is an expanding approach for managing breast conservation because it offers improved cosmetic outcomes while maintaining oncological safety.
OBJECTIVES: This study aimed to assess the oncological and surgical outcomes of patients who underwent oncoplastic procedures at a single institution.
METHODS: The study population includes all consecutive breast cancer patients who underwent lumpectomy followed by immediate oncoplastic breast reconstruction with contralateral breast adjustment between 2010 and 2021. Following IRB approval, patient demographics, tumor characteristics, surgical details, complications, and follow-up were evaluated for this group. Quality of life (QOL) and patient-reported outcome measures were assessed through questionnaires.
RESULTS: Following multidisciplinary tumor board discussion, 77 patients (82 breasts) underwent oncoplastic surgery. Of these, 92.2% underwent breast MRI prior to surgery with mean mass enhancement of 2.35 cm (range, 0-8.5 cm) and non-mass enhancement of 5.77 cm (range, 0-14 cm), and 44% presented with multifocal disease. The final positive surgical margin rate was 2.4%, and all conserved breasts received adjuvant radiation therapy. The 5-year local recurrence rate for invasive tumors was 4.1%. QOL scores were generally high, with most patients reporting good to excellent cosmetic outcomes and high personal satisfaction with breast appearance and softness. Physicians reported breast symmetry in 89.5%.
CONCLUSIONS: The findings suggest that oncoplastic surgery with contralateral breast adjustment is safe, effective, and an excellent option for breast cancer patients wishing for breast conservation even for large or multifocal masses, with favorable oncologic and cosmetic outcomes. The QOL analysis indicates high patient satisfaction. These results support the use of oncoplastic surgery in the management of breast cancer.
Patients were randomized in a 1:1:1 ratio to placebo, apremilast 20 mg BID and apremilast 30 mg BID. The duration of the study was approximately 5 years. The double blind period (when patients nor the physician knew whether placebo or apremilast was taken) was 24 weeks. At Week 16, participants who did not have either a ≥ 20% improvement or a ≥ 1 unit improvement from baseline in at least two of the four SpondyloArthritis international Society (ASAS) domains were entered in "early escape" from their current treatment in a double-blinded manner. However, such participants were permitted to continue in the study. At Week 24, participants may have entered a long-term extension phase for up to an additional 4.5 years (236 weeks). At "second escape" (at Week 24), apremilast 20 mg BID treated participants transitioned to receive double-blinded apremilast 30 mg BID and remained on double-blinded apremilast 30 mg BID because they continued to improve with a longer duration of treatment. After Week 24 and during the early portion of the long-term extension through Week 52, all participants continued on either double-blinded apremilast 20 mg BID or 30 mg BID treatment. After all participants had completed Week 52 or had terminated early from the study and the 52-week data base was locked, apremilast 20 mg BID or 30 mg BID treatment was provided.
The present invention relates to a psychological support rescue resource screening and allocation method and system, which mainly includes a communication unit, a voice unit, a storage unit, a receiving unit and an analysis and processing unit. A plurality of help seekers perform connections by using the communication unit. The voice unit is used for voice-mode inquiry to obtain basic personal information of each help seeker. The storage unit is configured to store the basic personal information of the help seekers, situational questions and a high-risk vocabulary database. The receiving unit receives a voice reply from the help seeker and outputs corresponding text data and audio data. The analysis and processing unit compares the received data with data in the high-risk vocabulary database and determines the highest-risk help seeker as the highest priority target for assistance. In this way, the person with the highest risk among the plurality of help seekers can be sorted as the highest priority target for assistances by senior ambulance personnel.
The present invention provides use of phenylquinolinone derivative or flavonoid derivative for neuropathic pain. The phenylquinolinone derivative or flavonoid derivative include pharmaceutically acceptable salts thereof. The compound of the present invention is a histamine H3 receptor antagonist, has a different mechanism of action from existing drugs, and can be used in the preparation of drugs for treating neuropathic pain diseases. The effect of the compound of the present invention for treating neuropathic pain is superior to that of amitriptyline, gabapentin, pregabalin and carbamazepine. Therefore, the compound of the present invention has a better treatment effect, and has the characteristics of a small dosage, good drug efficacy, high bioavailability and high safety. Compared with opioids, the compound of the present invention has no addiction property, and is a very effective drug for treating neuropathic pain diseases. Therefore, the compound has a great prospect in clinical application.
Aim of study: The effects of aldosterone blockade on myocardial remodeling in hypertensive patients with diastolic failing heart remains unclarified. Background: Nearly half of patients with clinical heart failure (HF) have normal left ventricular ejection fraction (LVEF) who usually present with apparent diastolic dysfunction (DD) and are referred as diastolic HF (DHF). Hypertensive heart disease occurs in the majority of patients with DHF, and several key aspects of heart failure secondary to hypertensive heart disease are the relatively highly prevalent LV hypertrophy, cardiac fibrosis, and endothelial dysfunction-mediated myocardial injury caused by changes in the local and systemic neurohormonal environment, and all of which are associated with LV diastolic dysfunction and tissue-Doppler derived systolic myocardial function. The renin-angiotensin-aldosterone system is an established major pathway that is operative in the pathogenesis of HF. The effects of aldosterone on myocardial hypertrophy, fibrosis and endothelial dysfunction have clearly been established in human and animal models. Furthermore, in these models, aldosterone antagonism prevented the development of myocardial fibrosis independent of its effect on blood pressure or myocardial hypertrophy. However, its application to patients with DHF is unspecified. In the study, we hypothesize that aldosterone blockade could reverse LV remodeling process in hypertensive patients with DHF.

Study protocol: We will enroll medically well-controlled hypertensive patients who have DHF defined as the presence of exertional dyspnea or HF signs/symptoms, diastolic dysfunction as impaired tissue-Doppler (TDI) derived mitral early annular diastolic velocity (\< 8 cm/s), and LVEF \> 50 % in echocardiography. All patients will be randomized to receive spironolactone 25 mg per day or not for at least 6 months. At baseline before randomization and 6 months after randomization, we will investigate the Quality-of-life (QOL) score by Minnesota Living with Heart Failure questionnaire (Chinese version), echocardiography coupled with TDI to assess the degree of LV hypertrophy, myocardial systolic and diastolic characteristics. Otherwise, we draw blood sampling at baseline and after randomization for quantifying and comparing several biomarkers which are currently proved to be correlated with LV hypertrophy, myocardial fibrosis, and biomechanical stretch in DHF patients, such as N-terminal pro-brain-type natriuretic peptide, matrix metalloproteinase-2, carboxy-terminal telopeptide, procollagen type III amino-terminal propeptide, soluble ST2, and galectin-3. Expected results: Aldosterone antagonism is effective for hypertensive patients with DHF by improving the quality of life, echo-derived myocardial function, and reducing ventricular mechanical stretch through lessening the degree of LV hypertrophy and myocardial fibrosis.
BACKGROUND: Frontonasal dysplasia (FND) is a rare congenital anomaly resulting from the underdevelopment of the frontonasal process, and it can be syndromic or nonsyndromic. The typical features of FND include a deformed nose and ocular hypertelorism, which are sometimes associated with cleft lip and/or palate. Only approximately 10 cases of prenatally diagnosed nonsyndromic FND have been reported in the past 30 years.
CASE PRESENTATION: A 33-year-old woman (G2P1) was referred to our center at 20 gestational weeks for bilateral hydrocephaly. We detected typical features of FND, including severe hypertelorism, median nasal bifidity, a minor cleft lip, and multiple limb anomalies using three-dimensional (3D) ultrasound. A hypoplastic corpus callosum, unilateral microtia, and a ventricular septal defect were also detected. Genetic testing, including karyotype analysis, copy number variation (CNV) analysis, trio-whole exome sequencing (trio-WES), and trio-whole-gene sequencing (trio-WGS), was performed; however, we did not find any de novo gene variants in the fetus as compared to the parents. Postmortem examination confirmed the prenatal diagnosis of FND.
CONCLUSION: The present case expands the wide phenotypic spectrum of prenatal FND patients. 3D ultrasound is a useful tool for detecting facial and limb deformities.
The invention discloses a traditional Chinese medicine composition for treating rhinitis, which comprises an external prescription and an internal prescription; the topical formulation comprises flos Magnoliae, fructus Xanthii, herba asari, etc.; the oral administration prescription comprises: centipeda minima, chrysanthemum, angelica dahurica, radix sileris, cimicifuga foetida and the like. The invention has good treatment effect on rhinitis by matching the internal medicine and the external medicine. The external medicine of the invention has the effects of dredging orifices, diminishing inflammation, promoting blood circulation and cooling blood, and can quickly and effectively treat symptoms of nasal obstruction and running nose; the internal medicine formula can tonify qi, invigorate spleen, eliminate dampness and expel pus, and fundamentally inhibit factors generating rhinitis. The invention is mainly used for treating various rhinitis diseases such as acute and chronic rhinitis, paranasal sinusitis, allergic rhinitis, chronic atrophic rhinitis, nasal polyp, nasal obstruction and the like. The oral and external formula is used together, the total effective force reaches 98 percent, and the cure rate is more than 89 percent.
Hemangioma depth evaluated by B-ultrasonoscope is lower than or equal to 6mm. After enrollment, patients would be subject to external use of Timolol Maleate 0.5% Oph Soln for the treatment of hemangioma.
In a 2-year study in Sprague-Dawley rats, albuterol sulfate caused a significant dose-related increase in the incidence of benign leiomyomas of the mesovarium at dietary doses of 2.0, 10, and 50 mg/kg (approximately ½, 2, and 10 times, respectively, the maximum recommended daily oral dose for adults and children, on a mg/m2 basis). In another study this effect was blocked by the coadministration of propranolol, a non-selective beta-adrenergic antagonist. In an 18-month study in CD-1 mice albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 500 mg/kg (approximately 60 times the maximum recommended daily oral dose for adults and children on a mg/m2 basis). In a 22-month study in the Golden hamster albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 50 mg/kg (approximately 8 times the maximum recommended daily oral dose for adults and children on a mg/m2 basis).

Albuterol sulfate was not mutagenic in the Ames test with or without metabolic activation using tester strains S. typhimurium TA1537, TA1538, and TA98 or E. coli WP2, WP2uvrA, and WP67. No forward mutation was seen in yeast strain S. cerevisiae S9 nor any mitotic gene conversion in yeast strain S. cerevisiae JD1 with or without metabolic activation. Fluctuation assays in S. typhimurium TA98 and E. coli WP2, both with metabolic activation, were negative. Albuterol sulfate was not clastogenic in a human peripheral lymphocyte assay or in an AH1 strain mouse micronucleus assay at intraperitoneal doses of up to 200 mg/kg.

Reproduction studies in rats demonstrated no evidence of impaired fertility at oral doses up to 50 mg/kg (approximately 15 times the maximum recommended daily oral dose for adults on a mg/m2 basis).
Aging is a multifaceted process characterized by the gradual decline of physiological functions and can be modulated by various internal and external factors. While social interactions have been shown to affect behaviors and physiology in different species, the impact of social partners on aging-related phenotypes and lifespan in mice remains understudied. To address this question, we investigated various aging-related traits and lifespan in two mouse strains, C57BL/6J and BALB/c, under two different housing conditions: mixed-strain and same-strain housing. Analyses using a Generalized Linear Model revealed significant differences between the two strains in several phenotypes, including metabolic, anxiety-like, and electrocardiographic traits. However, surprisingly, housing conditions did not significantly affect most of the examined parameters, including overall lifespan. Only 3 out of 25 traits-body weight change in a metabolic cage, running wheel activity, and survival days of a quartiles of mice with middle lifespans-were influenced by housing conditions in a strain-dependent manner. Together, our study suggested a minimal influence of co-housing with social partners from different genetic backgrounds on aging-related phenotypes. This result demonstrates the feasibility of mixed housing for mouse husbandry and, more importantly, provides valuable insights for future research on the social influences on the aging process in mice.
This intervention group will receive push notifications from a EMA behaviour monitoring mobile application that will be downloaded to each participants' mobile phones. The application will measure and monitor a participant's sedentary behaviour and once a pre-set condition of 30 consecutive sedentary minutes has been reached, the application will administer a push notification notifying the participant to break their sedentary behaviour. The push notifications will ask the participants to stand up, stretch, or lightly walk around to break their current behaviour. The intervention will last for three weeks.